Results 161 to 170 of about 28,388 (258)

Macrophage modulation with dipeptidyl peptidase-4 inhibitors: A new frontier for treating diabetic cardiomyopathy? [PDF]

World J Diabetes
Mohammadi S, Al-Harrasi A.
europepmc   +1 more source

Intestinal epithelial injury and inflammation after physical work in temperate and hot environments in older men with hypertension or type 2 diabetes

Experimental Physiology, EarlyView.
Abstract We tested whether older adults with well‐controlled type 2 diabetes or hypertension, compared with age‐matched adults without chronic disease, exhibit greater intestinal damage, microbial translocation and inflammation during exertional heat stress.
Ben J. Lee, Tessa R. Flood, Sophie L. Russell, James J. McCormick, Kelli E. King, Naoto Fujii, Tatsuro Amano, Sean Notley, Glen P. Kenny   +8 more
wiley   +1 more source

Evaluation of a Community Pharmacist-Led Intervention Program for Early Detection of Gastrointestinal Adverse Events of Dipeptidyl Peptidase-4 Inhibitors: A Multicenter, Non-Randomized Comparative Study. [PDF]

Pharmacy (Basel)
Funabashi A, Ito H, Maeda M, Hasegawa Y, Tsukioka R, Onda M.   +5 more
europepmc   +1 more source

Anti-Inflammatory and Survival Benefits of Dipeptidyl Peptidase 4 Inhibitors Among Patients with Gout, T2DM Patients and Chronic Kidney Disease. [PDF]

Exp Clin Endocrinol Diabetes
Shiber S, Sharabi A, Ayalon I, Naamany E, Grossman A, Molad Y.   +5 more
europepmc   +1 more source

Sodium–glucose cotransporter 2 inhibitors for hypertension in cardiovascular–kidney–metabolic syndrome

Experimental Physiology, EarlyView.
Abstract The antihypertensive mechanism of sodium–glucose cotransporter 2 (SGLT2) inhibitors has been traditionally attributed to osmotic diuresis. However, emerging evidence reveals multifaceted mechanisms beyond diuresis, including regulation of the renin–angiotensin–aldosterone system, sympathetic nervous system suppression, ion homeostasis ...
Chunxiang Xu, Xingyu Qiu, Nan Xu, Gensheng Zhang, Enyin Lai, Liang Zhao   +5 more
wiley   +1 more source

Association between dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists and COVID-19 infection and adverse outcomes: a cohort study. [PDF]

BMJ Open Diabetes Res Care
Thompson W, Yu B, Porter J, Fang J, Ferreira-Legere LE, Austin PC, Jackevicius CA, Ross H, Lee DS, Weisman A, Farkouh ME, Gershon AS, Atzema CL, Kwong JC, Ha A, Džavík V, Udell JA.   +16 more
europepmc   +1 more source

Effects of Oral Semaglutide on Dietary Intake and Body Composition in Japanese People With Type 2 Diabetes: A Prospective Observational Study in Clinical Practice

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.
This prospective observational study evaluated changes in dietary patterns and body composition after 3 months of oral semaglutide treatment in people with Type 2 diabetes. Oral semaglutide was associated with reduced energy intake, salt intake and body fat while preserving handgrip strength.
Mika Sawada, Naoko Nakanishi, Masakazu Aihara, Kanako Ohkuma, Shoko Hamano, Yoshitaka Sakurai, Rie Sekine, Satoshi Usami, Toshimasa Yamauchi, Naoto Kubota   +9 more
wiley   +1 more source

Efficacy and safety of bi-weekly cofrogliptin treatment replacing daily dipeptidyl peptidase-4 inhibitors in Chinese patients with type 2 diabetes mellitus: A multicenter, open-label, randomized controlled phase 2 trial. [PDF]

Diabetes Obes Metab
Pan C, Jiang H, Feng Y, Wang S, Zhang J, Wang Z, Zhou Y, Li F, Zhang Z, Li Y, Chen L.   +10 more
europepmc   +1 more source

Dipeptidyl Peptidase‐4 Inhibitors Associated Heart Failure Events in Adult Patients With Type‐2 Diabetes Mellitus Treated With Dipeptidyl Peptidase‐4 Inhibitors: A Systematic Review and Meta‐Analysis

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.
DPP‐4 Inhibitors associated withheart failure events in patients with type‐2 diabetes. This study found statistically insignificant summary effect for all DPP‐4 inhibitors combined but found asignificant association of saxagliptin with heart failure events (RR = 1.24, 95% CI 1.05–1.47). Results are to be interpreted with caution.
Shishir Nepal, Shiva Prasad Nepal
wiley   +1 more source

Glucagon-like peptide-1 receptor agonists, but not dipeptidyl peptidase-4 inhibitors, reduce alcohol intake. [PDF]

J Clin Invest
Farokhnia M, Tazare J, Pince CL, Bruns N, Gray JC, Lo Re V, Fiellin DA, Kranzler HR, Koob GF, Justice AC, Vendruscolo LF, Rentsch CT, Leggio L.   +12 more
europepmc   +1 more source